SCHEMBL5458349

SCHEMBL5458349

Cc1ccc(NC(=O)Nc2sc3c(c2C(N)=O)CCC(O)C3)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.57
KDM4E B2RXH2 2/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
HTT P42858 2/20 0.57
USP2 O75604 1/20 0.57
LMNA P02545 1/20 0.57
ATM Q13315 1/20 0.57
TNIK Q9UKE5 1/20 0.54
KCNH2 Q12809 12/20 0.51
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
FLT3 P36888 1/20 0.45
DUSP3 P51452 1/20 0.44
PTPN5 P54829 1/20 0.44
PTPN11 Q06124 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453345 0.82 TNIK (0.59) MAPTKDM4EMEN1KMT2ATNIK
SCHEMBL5451267 0.82 TNIK (0.59) MAPTKDM4ETNIKKCNH2CYP3A4
SCHEMBL5448399 0.82 TNIK (0.62) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL5752965 0.81 TNIK (0.74) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL5459994 0.81 TNIK (0.74) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL5446149 0.81 TNIK (0.74) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL5446191 0.81 TNIK (0.59) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL5453529 0.81 TNIK (0.59) MAPTTNIKKCNH2FLT3DUSP3
SCHEMBL5459133 0.81 TNIK (0.59) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL5453491 0.81 TNIK (0.52) MAPTKDM4EMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885KDM4E 3417/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.